European Society for Blood and Marrow Transplantation (EBMT)

Updated 52-week follow-up data were presented at the EBMT meeting.

The chief executive officer of Gamida Cell discussed upcoming research on 2 of their investigational agents, GDA-201 and omidubicel, for hematological malignancies.

The chief executive officer of Gamida Cell discussed the company's novel approach to cell proliferation.